

Miguel Munoz

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3761963/publications.pdf>

Version: 2024-02-01

69
papers

2,549
citations

186209

28
h-index

206029

48
g-index

72
all docs

72
docs citations

72
times ranked

1732
citing authors

#	ARTICLE	IF	CITATIONS
1	Involvement of substance P and the NK-1 receptor in human pathology. <i>Amino Acids</i> , 2014, 46, 1727-1750.	1.2	174
2	A conceptually new treatment approach for relapsed glioblastoma: Coordinated undermining of survival paths with nine repurposed drugs (CUSP9) by the International Initiative for Accelerated Improvement of Glioblastoma Care. <i>Oncotarget</i> , 2013, 4, 502-530.	0.8	152
3	Involvement of substance P and the NK-1 receptor in cancer progression. <i>Peptides</i> , 2013, 48, 1-9.	1.2	125
4	The NK-1 receptor antagonist aprepitant as a broad spectrum antitumor drug. <i>Investigational New Drugs</i> , 2010, 28, 187-193.	1.2	120
5	Hepatoblastoma cells express truncated neurokinin-1 receptor and can be growth inhibited by aprepitant in vitro and in vivo. <i>Journal of Hepatology</i> , 2014, 60, 985-994.	1.8	97
6	The NK-1 Receptor Is Expressed in Human Primary Gastric and Colon Adenocarcinomas and Is Involved in the Antitumor Action of L-733,060 and the Mitogenic Action of Substance P on Human Gastrointestinal Cancer Cell Lines. <i>Tumor Biology</i> , 2008, 29, 245-254.	0.8	86
7	The NK1 receptor is involved in the antitumoural action of L-733,060 and in the mitogenic action of substance P on neuroblastoma and glioma cell lines. <i>Neuropeptides</i> , 2005, 39, 427-432.	0.9	84
8	The NK-1 receptor is expressed in human melanoma and is involved in the antitumor action of the NK-1 receptor antagonist aprepitant on melanoma cell lines. <i>Laboratory Investigation</i> , 2010, 90, 1259-1269.	1.7	84
9	A New Frontier in the Treatment of Cancer: NK-1 Receptor Antagonists. <i>Current Medicinal Chemistry</i> , 2010, 17, 504-516.	1.2	83
10	The substance P/NK-1 receptor system: NK-1 receptor antagonists as anti-cancer drugs. <i>Journal of Biosciences</i> , 2015, 40, 441-463.	0.5	79
11	The NK-1 Receptor: A New Target in Cancer Therapy. <i>Current Drug Targets</i> , 2011, 12, 909-921.	1.0	76
12	NK-1 receptor antagonists induce apoptosis and counteract substance P-related mitogenesis in human laryngeal cancer cell line HEP-2. <i>Investigational New Drugs</i> , 2008, 26, 111-118.	1.2	73
13	The substance P/neurokinin-1 receptor system in lung cancer: Focus on the antitumor action of neurokinin-1 receptor antagonists. <i>Peptides</i> , 2012, 38, 318-325.	1.2	61
14	The neurokinin-1 receptor antagonist aprepitant is a promising candidate for the treatment of breast cancer. <i>International Journal of Oncology</i> , 2014, 45, 1658-1672.	1.4	61
15	Antitumoral action of the neurokinin-1 receptor antagonist L-733 060 on human melanoma cell lines. <i>Melanoma Research</i> , 2004, 14, 183-188.	0.6	60
16	Antitumoral Action of the Neurokinin-1-Receptor Antagonist L-733,060 and Mitogenic Action of Substance P on Human Retinoblastoma Cell Lines. , 2005, 46, 2567.		56
17	Neurokinin-1 Receptors Located in Human Retinoblastoma Cell Lines: Antitumor Action of Its Antagonist, L-732,138. , 2007, 48, 2775.		55
18	The Role of Neurokinin-1 Receptor in the Microenvironment of Inflammation and Cancer. <i>Scientific World Journal</i> , The, 2012, 2012, 1-21.	0.8	54

#	ARTICLE	IF	CITATIONS
19	The Neurokinin-1 Receptor Antagonist Aprepitant: An Intelligent Bullet against Cancer?. <i>Cancers</i> , 2020, 12, 2682.	1.7	52
20	NK-1 Receptor Antagonists: A New Paradigm in Pharmacological Therapy. <i>Current Medicinal Chemistry</i> , 2011, 18, 1820-1831.	1.2	49
21	Antitumor activity of neurokinin-1 receptor antagonists in MG-63 human osteosarcoma xenografts. <i>International Journal of Oncology</i> , 2014, 44, 137-146.	1.4	47
22	Expression of substance P and neurokinin-1 receptor in laryngeal cancer: linking chronic inflammation to cancer promotion and progression. <i>Histopathology</i> , 2009, 54, 258-260.	1.6	46
23	Safety of neurokinin-1 receptor antagonists. <i>Expert Opinion on Drug Safety</i> , 2013, 12, 673-685.	1.0	42
24	A role for the substance P/NK-1 receptor complex in cell proliferation in oral squamous cell carcinoma. <i>Anticancer Research</i> , 2009, 29, 2323-9.	0.5	41
25	The NK-1 receptor is expressed in human leukemia and is involved in the antitumor action of aprepitant and other NK-1 receptor antagonists on acute lymphoblastic leukemia cell lines. <i>Investigational New Drugs</i> , 2012, 30, 529-540.	1.2	39
26	Cancer progression and substance P. <i>Histology and Histopathology</i> , 2014, 29, 881-90.	0.5	38
27	Antitumor action of temozolomide, ritonavir and aprepitant against human glioma cells. <i>Journal of Neuro-Oncology</i> , 2016, 126, 425-431.	1.4	35
28	Involvement of substance P and the NK-1 receptor in pancreatic cancer. <i>World Journal of Gastroenterology</i> , 2014, 20, 2321.	1.4	35
29	The NK-1 Receptor is Involved in the Antitumoural Action of L-733,060 and in the Mitogenic Action of Substance P on Human Pancreatic Cancer Cell Lines. <i>Letters in Drug Design and Discovery</i> , 2006, 3, 323-329.	0.4	32
30	Neurokinin-1 receptor: a new promising target in the treatment of cancer. <i>Discovery Medicine</i> , 2010, 10, 305-13.	0.5	28
31	Neurokinin receptor antagonism: a patent review (2014-present). <i>Expert Opinion on Therapeutic Patents</i> , 2020, 30, 527-539.	2.4	26
32	Neurokinin-1 receptor antagonists as antitumor drugs in gastrointestinal cancer: A new approach. <i>Saudi Journal of Gastroenterology</i> , 2016, 22, 260.	0.5	25
33	Immunolocalization of NK-1 Receptor and Substance P in Human Normal Placenta. <i>Placenta</i> , 2010, 31, 649-651.	0.7	24
34	NK-1 receptor antagonists as antitumor drugs: a survey of the literature from 2000 to 2011. <i>Expert Opinion on Therapeutic Patents</i> , 2012, 22, 735-746.	2.4	23
35	The Neurokinin-1 Receptor Antagonist Aprepitant, a New Drug for the Treatment of Hematological Malignancies: Focus on Acute Myeloid Leukemia. <i>Journal of Clinical Medicine</i> , 2020, 9, 1659.	1.0	23
36	Human acute myeloid leukemia cells express Neurokinin-1 receptor, which is involved in the antileukemic effect of Neurokinin-1 receptor antagonists. <i>Investigational New Drugs</i> , 2019, 37, 17-26.	1.2	22

#	ARTICLE	IF	CITATIONS
37	Primary leptomeningeal melanoma in a child. <i>Pediatric Neurology</i> , 2001, 24, 390-392.	1.0	21
38	Neurokinin-1 Receptor Antagonists against Hepatoblastoma. <i>Cancers</i> , 2019, 11, 1258.	1.7	21
39	Paravertebral anesthesia: how substance P and the NK-1 receptor could be involved in regional block and breast cancer recurrence. <i>Breast Cancer Research and Treatment</i> , 2010, 122, 601-603.	1.1	20
40	Kluyvera Meningitis in a Newborn. <i>Pediatric Infectious Disease Journal</i> , 2007, 26, 1070-1071.	1.1	17
41	The NK-1 Receptor Antagonist L-732,138 Induces Apoptosis and Counteracts Substance P-Related Mitogenesis in Human Melanoma Cell Lines. <i>Cancers</i> , 2010, 2, 611-623.	1.7	17
42	The NK-1 receptor antagonist L-732,138 induces apoptosis in human gastrointestinal cancer cell lines. <i>Pharmacological Reports</i> , 2017, 69, 696-701.	1.5	17
43	Neurokinin-1 receptor antagonist aprepitant and radiotherapy, a successful combination therapy in a patient with lung cancer: A case report. <i>Molecular and Clinical Oncology</i> , 2019, 11, 50-54.	0.4	16
44	Primary idiopathic chylopericardium in a 2 month old successfully treated without surgery. <i>Journal of Pediatric Surgery</i> , 2000, 35, 646-648.	0.8	14
45	NK-1 as a melanoma target. <i>Expert Opinion on Therapeutic Targets</i> , 2011, 15, 889-897.	1.5	14
46	Targeting NK-1 Receptors to Prevent and Treat Pancreatic Cancer: a New Therapeutic Approach. <i>Cancers</i> , 2015, 7, 1215-1232.	1.7	13
47	The broad-spectrum antitumor action of cyclosporin A is due to its tachykinin receptor antagonist pharmacological profile. <i>Peptides</i> , 2010, 31, 1643-1648.	1.2	12
48	NK-1 Receptor Antagonists: A New Generation of Anticancer Drugs. <i>Mini-Reviews in Medicinal Chemistry</i> , 2012, 12, 593-599.	1.1	12
49	Antipruritic vs. Antitumour Action of Aprepitant: A Question of Dose. <i>Acta Dermato-Venereologica</i> , 2019, 99, 620-621.	0.6	12
50	The substance P and neurokinin-1 receptor system in human thyroid cancer: an immunohistochemical study. <i>European Journal of Histochemistry</i> , 2020, 64, .	0.6	12
51	Substance P and Neurokinin 1 Receptor in Chronic Inflammation and Cancer of the Head and Neck: A Review of the Literature. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 375.	1.2	12
52	Seizures caused by chloral hydrate sedative doses. <i>Journal of Pediatrics</i> , 1997, 131, 787-788.	0.9	11
53	Immunolocalization of Substance P and NK-1 Receptor in ADIPOSE Stem Cells. <i>Journal of Cellular Biochemistry</i> , 2017, 118, 4686-4696.	1.2	11
54	The Neurokinin-1 Receptor Is Essential for the Viability of Human Glioma Cells: A Possible Target for Treating Glioblastoma. <i>BioMed Research International</i> , 2022, 2022, 1-13.	0.9	11

#	ARTICLE	IF	CITATIONS
55	Increased nuclear localization of substance P in human gastric tumor cells. <i>Acta Histochemica</i> , 2017, 119, 337-342.	0.9	10
56	Uveal melanoma expresses NK-1 receptors and cyclosporin A induces apoptosis in human melanoma cell lines overexpressing the NK-1 receptor. <i>Peptides</i> , 2014, 55, 1-12.	1.2	8
57	Triple Negative Breast Cancer: How Neurokinin-1 Receptor Antagonists Could Be Used as a New Therapeutic Approach. <i>Mini-Reviews in Medicinal Chemistry</i> , 2020, 20, 408-417.	1.1	8
58	Glioma and Neurokinin-1 Receptor Antagonists: A New Therapeutic Approach. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2019, 19, 92-100.	0.9	8
59	Immunolocalization of substance P and NK-1 receptor in Hofbauer cells in human normal placenta. <i>Microscopy Research and Technique</i> , 2013, 76, 1310-1313.	1.2	7
60	Neurokinin-1 Receptor Antagonists as Anticancer Drugs. <i>Letters in Drug Design and Discovery</i> , 2019, 16, 1110-1129.	0.4	6
61	Why Use Aprepitant Only as a Cough Suppressant in Lung Cancer When at Higher Doses it Could Also Exert an Antitumor Action?. <i>Archivos De Bronconeumologia</i> , 2022, 58, 727-728.	0.4	6
62	Immunolocalization of substance P and NK-1 receptor in vascular anomalies. <i>Archives of Dermatological Research</i> , 2017, 309, 97-102.	1.1	5
63	Prognostic Significance of Substance P/Neurokinin 1 Receptor and Its Association with Hormonal Receptors in Breast Carcinoma. <i>BioMed Research International</i> , 2021, 2021, 1-11.	0.9	5
64	Neurokinin-1 Receptor. , 2018, , 3437-3445.		4
65	Neurokinin-1 Receptor Antagonists in Lung Cancer Therapy. <i>Letters in Drug Design and Discovery</i> , 2017, 14, .	0.4	4
66	Substance P. , 2018, , 571-578.		2
67	Substance P – Friend or Foe. <i>Journal of Clinical Medicine</i> , 2022, 11, 3609.	1.0	1
68	Resistance to a beta-lactam antibiotic appearing during therapy for enterobacter cloacae sepsis in a child. <i>Medical and Pediatric Oncology</i> , 2003, 40, 62-63.	1.0	0
69	Neurokinin-1 Receptor. , 2016, , 1-8.		0